Volume 27, Number 10—October 2021
Synopsis
Characteristics, Comorbidities, and Data Gaps for Coronavirus Disease Deaths, Tennessee, USA
John James Parker
, Rany Octaria, Miranda D. Smith, Samantha J. Chao, Mary Beth Davis, Celia Goodson, Jon Warkentin, Denise Werner, and Mary-Margaret A. Fill
, Rany Octaria, Miranda D. Smith, Samantha J. Chao, Mary Beth Davis, Celia Goodson, Jon Warkentin, Denise Werner, and Mary-Margaret A. Fill
Table 3
Characteristics and comorbidities for patients with coronavirus disease, Tennessee, USA*
| Characteristic | Coronavirus disease deaths |
|
|---|---|---|
| Standard surveillance, n = 1,255 | Chart-abstracted, n = 188 | |
| Race and ethnicity, no. (%)† | ||
| White, non-Hispanic | 787 (62.7) | 109 (58.0) |
| Black, non-Hispanic | 365 (29.1) | 63 (33.6) |
| Hispanic (all races) |
74 (5.9) |
10 (5.3) |
| Sex, no. (%) | ||
| F | 549 (43.7) | 79 (42.0) |
| M |
706 (56.3) |
109 (58.0) |
| Mean age, y, (SD) |
73.6 (13.9) |
72.7 (14.4) |
| Current/former smoker, no. (%) |
192 (15.3) |
57 (30.3) |
| Mean no. (SD) comorbidities |
2.0 (1.5) |
2.9 (1.6) |
| Age group, y, has any comorbidity, no. (%)† | ||
| 21–64: Nss = 284; Nca = 50 | 205 (72.2) | 47 (94.0) |
| 65–80: Nss = 505; Nca = 63 | 404 (80) | 62 (98.4) |
| >81: Nss = 465; Nca = 74 | 382 (82.2) | 72 (97.3) |
| All ages: Nss = 1,254; Nca = 188 |
991 (79.0) |
181 (96.3) |
| Comorbidities, no. (%) | ||
| Hypertension | 630 (50.2) | 144 (76.6) |
| Cardiovascular disease‡ | 509 (40.6) | 102 (54.3) |
| Chronic lung disease§ | 257 (20.5) | 56 (29.8) |
| Diabetes mellitus | 459 (36.6) | 75 (39.9) |
| Obesity | 156 (12.4) | 42 (22.3) |
| Cancer | 54 (4.3) | 20 (10.6) |
| Chronic renal disease | 238 (19.0) | 51 (27.1) |
| Chronic liver disease | 34 (2.7) | 6 (2.7) |
| Immunocompromised | 76 (6.1) | 18 (9.6) |
| Autoimmune diseases | 21 (1.7) | 8 (4.3) |
| HIV/AIDS | 5 (0.4) | 1 (0.5) |
*Nca, no. patients who had chart abstraction for that age group; Nss, no. patients who had standard surveillance for that age group. †Cell percent is the percentage in that age group (i.e., for standard surveillance case-patients 21–64 years of age, the percentage is 205/284). ‡Defined as coronary artery disease, cerebrovascular, peripheral artery disease, heart failure, cardiomyopathies, valvular disease, myocarditis, and arrythmias. Hypertension is listed separately. §Defined as asthma, chronic obstructive pulmonary disease, emphysema, pulmonary hypertension, interstitial fibrosis, or sarcoidosis.
Page created: July 06, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.